Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing–Remitting Multiple Sclerosis Patients

AIMS: Fingolimod, oral treatment for relapsing–remitting multiple sclerosis (RRMS), is an agonist of sphingosine and its metabolite S1P that binds their receptors, blocking the egress of lymphocytes from lymph nodes. The aim of this study was immunomonitoring of minor peripheral lymphocyte subpopula...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CNS Neurosci Ther
Egile Nagusiak: Teniente‐Serra, Aina, Hervás, José Vicente, Quirant‐Sánchez, Bibiana, Mansilla, María José, Grau‐López, Laia, Ramo‐Tello, Cristina, Martínez‐Cáceres, Eva María
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2016
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492868/
https://ncbi.nlm.nih.gov/pubmed/27080413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12548
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak